Drug Profile
Research programme: antiviral therapeutics - SIGA
Alternative Names: ST-148; ST-193; ST-294; ST-383; ST-610; ST-669Latest Information Update: 23 Sep 2014
Price :
$50
*
At a glance
- Originator SIGA Technologies
- Class Benzimidazoles; Small molecules
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Bunyavirus infections; Dengue; Ebola virus infections; Junin virus infections; Lassa fever; Marburg virus disease; Viral infections
Most Recent Events
- 24 Aug 2011 SIGA technologies receives grant from National Institutes of Health (NIH) for antiviral drug development in Lassa fever and other haemorrhagic fevers of Arenavirus origin
- 25 Feb 2010 SIGA Technologies receives funding from the US Department of Defense for ST 669 development in Viral infections
- 25 Feb 2010 Preclinical trials in Viral infections in USA (unspecified route)